-
Study aim
-
The effects of melatonin supplementation on lipid profile, glycemic index, oxidative stress and inflammatory biomarkers in obese patients with type 2 diabetes
-
Design
-
Clinical trial with a control group, with parallel groups, double-blind, randomized, phase 3 on 46 patients. Sealedenvelope.com is used for randomization.
-
Settings and conduct
-
Patients at Shariati Hospital in Tehran are randomly selected for a study. Both groups receive supplements and are monitored over a 12-week period. The main outcome variables are measured and compared at the start and end of the study.
-
Participants/Inclusion and exclusion criteria
-
Entry requirements:
1. At least 6 months and a maximum of 10 years have passed since the diagnosis of the disease by a doctor.
2. Having diabetes diagnosed based on laboratory findings and the opinion of an endocrinologist.
3. Being willing to cooperate in this study
4. Age above 30 and below 60 years
5. Body mass index above 30 and below 40 kg/m2
6. Patients who are not candidates for bariatric surgery
Non-entry conditions:
Pregnancy, breastfeeding, or plans to become pregnant within 6 months.
History of infectious or inflammatory diseases, thyroid disorders, or thrombocytopenia.
Receiving enteral or parenteral nutritional support.
Taking omega-3 supplements or antioxidant vitamins.
Use of glucocorticoid drugs, NSAIDs, thyroxine, or warfarin.
Patients who change their drug dosage or type during the study.
-
Intervention groups
-
In this study, the intervention group receives two 5 mg melatonin supplements daily, while the control group receives two placebo capsules that mimic melatonin in appearance, color, smell, and taste, for a period of 10 weeks.
-
Main outcome variables
-
Oxidative stress and Inflammatory markers, Blood sugar, lipid, anthropometry, systolic and diastolic blood pressure, sleep quality score and ASCVD and Framingham criteria.